Howard L. Kaufman

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Igor Puzanov, Adi Diab, K. Abdallah et al. · Journal for ImmunoTherapy of Cancer · 2017 · 2K citations · Full text

Life Sciences, Immunology, Oncology +17

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +11

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Douglas J. Schwartzentruber, David H. Lawson, Jon Richards et al. · New England Journal of Medicine · 2011 · 888 citations

Medicine, Immunology, Oncology +14

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott et al. · JAMA Oncology · 2015 · 656 citations

Life Sciences, Immunology, Oncology +15

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Jason Chesney, Igor Puzanov, Frances A. Collichio et al. · Journal of Clinical Oncology · 2017 · 617 citations

Medicine, Oncology, Pharmacotherapy +17